Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Real world evidence: what is it and what can it tell us?

Kwee Yong • 5 Oct 2018
ESH MM 2018
Multiple Myeloma

The importance of real world data is becoming increasingly apparent. Here, Kwee Yong, PhD, FRCP, FRCPath, from University College London, London, UK, discusses real world evidence and the many reasons why it is essential, in addition to clinical trial data. This interview was recorded at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.

More from Kwee Yong

Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
0:42
Looking forward to EHA 2022: updates in multiple myeloma
Kwee Yong • 14 May 2022
3:05
Recent advances in newly diagnosed multiple myeloma and the importance of patient perspectives
Kwee Yong • 14 May 2022
2:00
Combining bortezomib and lenalidomide-based regimens for frontline MM
Kwee Yong • 5 Oct 2018

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals